In a late-stage trial, Eli Lilly (LLY) says Zepbound, its obesity pill, significantly eased obstructive sleep apnea severity among patients with obesity.

Observed price moves

• LLY+0.60%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.